- Home
- CURI vs GLUE Comparison
CURI vs GLUE Comparison
Compare CURI & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- GLUE
- Stock Information
- Founded
- CURI N/A
- GLUE 2019
- Country
- CURI United States
- GLUE United States
- Employees
- CURI N/A
- GLUE N/A
- Industry
- CURI Movies/Entertainment
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- GLUE Health Care
- Exchange
- CURI Nasdaq
- GLUE Nasdaq
- Market Cap
- CURI 257.8M
- GLUE 308.8M
- IPO Year
- CURI N/A
- GLUE 2021
- Fundamental
- Price
- CURI $4.07
- GLUE $12.05
- Analyst Decision
- CURI Strong Buy
- GLUE Buy
- Analyst Count
- CURI 3
- GLUE 2
- Target Price
- CURI $6.00
- GLUE $13.50
- AVG Volume (30 Days)
- CURI 464.2K
- GLUE 1.3M
- Earning Date
- CURI 11-12-2025
- GLUE 11-07-2025
- Dividend Yield
- CURI 7.62%
- GLUE N/A
- EPS Growth
- CURI N/A
- GLUE N/A
- EPS
- CURI N/A
- GLUE 0.29
- Revenue
- CURI $60,840,000.00
- GLUE $177,986,000.00
- Revenue This Year
- CURI $36.83
- GLUE $66.94
- Revenue Next Year
- CURI $9.44
- GLUE N/A
- P/E Ratio
- CURI N/A
- GLUE $40.97
- Revenue Growth
- CURI 11.02
- GLUE 2990.57
- 52 Week Low
- CURI $1.47
- GLUE $3.50
- 52 Week High
- CURI $7.15
- GLUE $13.22
- Technical
- Relative Strength Index (RSI)
- CURI 34.58
- GLUE 67.66
- Support Level
- CURI $4.39
- GLUE $8.94
- Resistance Level
- CURI $4.78
- GLUE $13.22
- Average True Range (ATR)
- CURI 0.21
- GLUE 0.86
- MACD
- CURI -0.05
- GLUE 0.04
- Stochastic Oscillator
- CURI 1.26
- GLUE 73.58
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.